Skip to main content
SpringerLink
Log in

Glucose tolerance, plasma insulin and lipids in diabetic subjects before and after treatment with a new sulfonylurea compound, Ro 6-4563

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The effects of a new sulfonylurea (Ro 6-4563) have been studied on glucose tolerance, plasma insulin, lipids, and lipoprotein pattern in 29 patients with maturity onset diabetes. After 4 weeks of treatment 3 different reactions have been distinguished and are discussed: I. No response, viz. same glucose tolerance and insulin levels before and after treatment. II. Improved glucose tolerance without increased insulin levels. III. Improved glucose tolerance with higher insulin levels. Sulfonylurea treatment had no effect on plasma lipids or lipoprotein pattern. Clinically “good blood sugar control” could not be correlated with good lipid control. Response II supports the view that sulfonylurea compounds do not necessarily act by increasing plasma insulin levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abramson, E., Arky, R.A.: Treatment of obese diabetics, a comparative study of placebo, sulfonylurea and phenformin. Metabolism16, 204–212 (1967).

    Google Scholar 

  2. Anderson, J., Coulsen, R., Grassick, B.D.M., Morris, B.A., Thomas, W.D., Tomlinson, R.W.S., Woodroffe, F.: Clinical and metabolic study in diabetic patients treated with glibenclamide. Brit. med. J.1971 II, 568–570.

    Google Scholar 

  3. Appels, A., Kattermann, R., Proschek, H., Hubrich, K., Frerichs, H., Söling, H.D., Creutzfeldt, W.: Untersuchungen über die Wirkung von Diät, Tolbutamid und Buformin, sowie deren Kombination auf Körpergewicht und verschiedene Stoffwechselgrößen bei Diabetikern. I. Körpergewicht, Kohlenhydratstoffwechsel und immunologisch reagierendes Insulin. Diabetologia4, 210–220 (1968).

    Google Scholar 

  4. Bagdade, J.D., Bierman, E.L., Porte, D.: The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J. clin. Invest.46, 1549–1557 (1967).

    Google Scholar 

  5. Belknap, B.H., Bagdade, J.D., Amaral, J.A.P., Bierman, E.L.: Plasma lipids and mild glucose intolerance. II. A double blind study of the effect of tolbutamide and placebo in mild adult diabetic outpatients. In: Butterfield, W.J.H., van Westering, W. (ed.) Tolbutamide ... after ten years, p. 171. Amsterdam Excerpta Med. Found. 1967.

    Google Scholar 

  6. Berchtold, P., Büber, V., Meier, V., Felber, J.-P., Keiser, G.: Vergleichende Untersuchungen über den oralen und intravenösen Tolbutamidtest. II. Bestimmung von Glucose, Serum-Insulin und Serum-Tolbutamid bei normalen, jungen Probanden. Diabetologia,7, 77–81 (1971)a.

    Google Scholar 

  7. —— Björntorp, P., Gustafson, A., Jonsson, A., Fagerberg, S.-E.: Effects of a new sulfonylurea compound Ro 6-4563 and glibenclamide on glucose tolerance, plasma insulin and plasma lipids in diabetic subjects. Diabetes20, 348 (1971) b, Abstract.

    Google Scholar 

  8. Björntorp, P., Berchtold, P., Tibblin, G.: Plasma insulin in relation to adipose tissue in men. Diabetes20, 65–70 (1971).

    Google Scholar 

  9. Bowers, C.Y., Muldrey, J.E., Hamilton, J.G.: Blood lipids and glucose levels of patients with diabetes mellitus treated with chloropropamide. Amer. J. med. Sci.274, 676–681 (1964).

    Google Scholar 

  10. Bückert, A., Lorch, E., Pometta, J., Dubach, U.C., Zahnd, G., Berger, W., Lunell, N.D.: Tierexperimentelle und humanpharmakologische Untersuchungen mit einem neuen Sulfonylharnstoffderivat Ro 6-4563. 5th annual meeting Europ. Assoc. Study Diabetes, Abstract No. 23, Montpellier 1969.

  11. Carlson, L.A., Wadström, L.B.: Determination of glycerides in blood serum. Clin. chim. Acta4, 197–205 (1959).

    Google Scholar 

  12. Cerasi, E., Luft, R.: Plasma insulin responses to glucose infusions in healthy subjects and in diabetes mellitus. Acta endocr. (Kbh)55, 278–304 (1967).

    Google Scholar 

  13. Chabot, V., Büber, V., Felber, J.P.: Some new aspects of the hypoglycemic action of tolbutamide. 7th Congress of the internat. Diabetes Federation. Buenos Aires, Excerpta Med. Found, Int. Congr. Series No. 209, 1970, abstract 193.

  14. Chandalia, H.B., Hollobaugh, S.L., Pennington, L.F., Boshell, B.R.: Use of glibenclamide in maturity onset diabetes. Effect of the drug on serum insulin levels. Horm. metab. res.1, suppl.1, 73–76 (1969).

    Google Scholar 

  15. Chu, P.C., Conway, M.J., Krouse, H.A., Goodner, C.J.: The pattern of response of plasma insulin and glucose to meals and fasting during chlorpropamide therapy. Ann. intern. Med.68, 757–769 (1968).

    Google Scholar 

  16. Cramér, C., Isaksson, B.: An evaluation of the Theorell method for the determination of serum cholesterol. Scand. J. clin. Lab. Invest.11, 213–216 (1959).

    Google Scholar 

  17. Davidson, M., Lewis, A.A.G., De Mobray, R.R., Boucher, B., Oakley, N.W., Nabarro, J.D.N., Ginsberg, J., Beaconsfield, P.: Metabolic and clinical effects of glibenclamide. Lancet1970 I, 57–61.

    Google Scholar 

  18. Feldman, J.M., Lebovitz, H.E.: Appraisal of the extrapancreatic actions of sulfonylureas. Arch. intern. Med.123, 314–322 (1969).

    Google Scholar 

  19. Ferguson, B.D.: The oral hypoglycemic compounds. Med. clin. N. Amer.49, 929–938 (1965).

    Google Scholar 

  20. Fredrickson, D.S., Lees, R.S.: A system for phenotyping hyperlipoproteinemia. Circulation31, 321–327 (1965).

    Google Scholar 

  21. Floyd, J.C., Fajans, S.S., Conn, J.W., Thiffault, C., Knopf, R.F., Guntsche, E.: Secretion of insulin induced by amino acids and glucose in diabetes mellitus. J. clin. Endocr.28, 266–276 (1968).

    Google Scholar 

  22. Furman, R.H., Alaupovic, P., Gustafson, A.: Lipoproteins in different forms of hyperlipemia. In Schettler, G. and Sanwald, R. (ed.) “Pathophysiological and Clinical Aspects of Lipid Metabolism”. Stuttgart: Georg Thieme 1965.

    Google Scholar 

  23. Hales, C.N., Randle, P.J.: Immunoassay of insulin with insulin antibody precipitate. Lancet1963 I, 200.

    Google Scholar 

  24. Johnson, B.F., Bhatia, C.K., Rzeszotarski, W.J., Wolff, F.W.: Preliminary clinical evaluation of glybenclamide in treatment of diabetes mellitus. Diabetes19, 579–584 (1970).

    Google Scholar 

  25. Kipnis, D.M.: Insulin secretion in diabetes mellitus. Ann. intern. Med.69, 891–901 (1968).

    Google Scholar 

  26. Lees, R.S., Hatch, F.T.: Sharper separation of lipoprotein species by paperelectrophoresis in albumin containing buffer. J. Lab. clin. Med.61, 518–528 (1963).

    Google Scholar 

  27. Levin, K., Linde, S.: Determination of glucose in blood, cerebrospinal fluid and urine with a new glucose oxidase reagent. J. swed. Med. Assoc.59, 3016–3026 (1962).

    Google Scholar 

  28. Loubatières, A.: Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides. In: Loubatières, A., Renold, A. E.: Pharmacokinetics and mode of action of oral hypoglycemic agents. Acta diabet. lat.6, suppl.1, 216–255 (1969).

    Google Scholar 

  29. Madsen, J.: Mode of action of blood glucose lowering sulfonamides. Other extrapancreatic effects. In: Loubatières, A., Renold, A.E.: Pharmacokinetics and mode of action of oral hypoglycemic agents. Acta diabet. lat.6, suppl.1, 415–428 (1969).

    Google Scholar 

  30. Mc Kiddie, M.T., Buchanan, K.D.: Plasma insulin studies in two hundred patients with diabetes mellitus. Quart. J. Med.38, 445–465 (1969).

    Google Scholar 

  31. Morris, J.H., West, D.A., Bolinger, R.E.: Effect of oral sulfonylurea on plasma triglycerides in diabetics. Diabetes13, 87–89 (1964).

    Google Scholar 

  32. Müller, W.A., Faloona, G.R., Aguilar-Parada, E., Unger, R.H.: Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. New Engl. J. Med.283, 109–115 (1970).

    Google Scholar 

  33. Pfeiffer, E.F.: Current pathophysiological and clinical aspects of the mode of action of blood sugar lowering sulfonamides. In: Loubatières, A., Renold, A.E.: Pharmacokinetics and mode of action of oral hypoglycemic agents. Acta diabet. lat.6, suppl.1, 477–504 (1969).

    Google Scholar 

  34. Phear, D.: The normal and diabetic patterns of insulin response to glucose. Lancet1962 II, 955–958.

    Google Scholar 

  35. Rapp, W., Kahlke, W.: Lipoprotein-electrophorese in agarose gel. Clin. chim. Acta19, 493–490 (1968).

    Google Scholar 

  36. Reaven, G., Dray, J.: Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity onset diabetes. Diabetes16, 487–492 (1967).

    Google Scholar 

  37. Salans, L.B., Reaven, G.M.: Effect of oral hypoglycemic agents on serum insulin-like activity of patients with various degrees of carbohydrate intolerance. Metabolism14, 26–30 (1965).

    Google Scholar 

  38. Samols, E., Tylor, J.M., Mialhe, P.: Suppression of pancreatic glucagon release by the hypoglycemic sulfonylureas. Lancet1969 I, 174–176.

    Google Scholar 

  39. Sheldon, J., Taylor, K.W., Anderson, J.: The effects of longterm acetohexamide treatment on pancreatic islet cell function in maturity-onset diabetes. Metabolism15, 874–883 (1966).

    Google Scholar 

  40. Shipp, J.C., Munroe, J.F.: Effects of sulfonylurea compounds on hyperlipemia and hypercholesterinemia in patients with minimal impairment of glucose tolerance. Diabetes11, suppl. 69–73 (1962).

    Google Scholar 

  41. Turtle, J.R.: Glucose and insulin secretory response patterns following diet and tolazamide therapy in diabetes. Brit. med. J.1970 606–610.

  42. Wajchenberg, B.L., Nakasone, K., Pasternak, K.: Effect of shortterm tolbutamide treatment on insulin dynamics in newly diagnosed obese and non obese adult diabetics. Horm. metab. res.2, 6–8 (1970).

    Google Scholar 

  43. Zeytinoglou, I., Gundersen, K.: Effect of tolazamide and tolbutamide on blood sugar and serum immunoreactive insulin levels during all day study. Diabetes15, 551 (1966) abstract.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Laboratory of Metabolic Research, First Medical Service, Sahlgren's Hospital, University of Gothenburg, Gothenburg, Sweden

    P. Berchtold, P. Björntorp, A. Gustafson, A. Jonsson & S. -E. Fagerberg

  2. Dept. of Pharmacology, University of Southern California Medical School, 2025 Zonal Avenue, 90 033, Los Angeles, Calif., USA

    P. Berchtold

Authors
  1. P. Berchtold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Björntorp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Gustafson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Jonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. -E. Fagerberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Research fellow supported by F. Hoffman - La Roche, Basle, Switzerland. Present address: Dept. of Pharmacology University of Southern California Medical School. 2025 Zonal Avenue, Los Angeles, Ca. 90 033 U.S.A.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berchtold, P., Björntorp, P., Gustafson, A. et al. Glucose tolerance, plasma insulin and lipids in diabetic subjects before and after treatment with a new sulfonylurea compound, Ro 6-4563. Eur J Clin Pharmacol 4, 22–28 (1971). https://doi.org/10.1007/BF00568894

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00568894

Key words

Search

Navigation